

Sahar Saeed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12187666/publications.pdf>

Version: 2024-02-01

28
papers

854
citations

586496

16
h-index

563245

28
g-index

31
all docs

31
docs citations

31
times ranked

1531
citing authors

#	ARTICLE	IF	CITATIONS
1	Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. <i>International Journal of Drug Policy</i> , 2022, 103, 103627.	1.6	6
2	SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. <i>Transfusion</i> , 2021, 61, 862-872.	0.8	48
3	Estimating an individual-level deprivation index for HIV/HCV coinfecting persons in Canada. <i>PLoS ONE</i> , 2021, 16, e0249836.	1.1	2
4	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. <i>PLoS ONE</i> , 2021, 16, e0257743.	1.1	13
5	Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, 363-371.	2.9	31
6	Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. <i>Aids</i> , 2020, 34, 237-244.	1.0	25
7	The 8th Canadian Symposium on Hepatitis C virus: "Improving diagnosis and linkage to care", <i>Canadian Liver Journal</i> , 2020, 3, 3-14.	0.3	1
8	Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. <i>Liver International</i> , 2019, 39, 2244-2260.	1.9	36
9	Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. <i>International Journal of Drug Policy</i> , 2019, 65, 41-49.	1.6	16
10	Evaluating the impact of health policies: using a difference-in-differences approach. <i>International Journal of Public Health</i> , 2019, 64, 637-642.	1.0	21
11	Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. <i>Journal of the International AIDS Society</i> , 2018, 21, e25051.	1.2	40
12	Segmented generalized mixed effect models to evaluate health outcomes. <i>International Journal of Public Health</i> , 2018, 63, 547-551.	1.0	18
13	The 7th Canadian Symposium on Hepatitis C Virus: "Toward Elimination of HCV: How to Get There", <i>Canadian Liver Journal</i> , 2018, 1, 139-152.	0.3	3
14	Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging. <i>PLoS ONE</i> , 2018, 13, e0195148.	1.1	6
15	Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1507-1514.	1.0	26
16	Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. <i>Journal of the International AIDS Society</i> , 2017, 20, e25013.	1.2	52
17	A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. <i>PLoS ONE</i> , 2017, 12, e0176282.	1.1	6
18	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. <i>CMAJ Open</i> , 2016, 4, E605-E614.	1.1	74

#	ARTICLE	IF	CITATIONS
19	How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. <i>Clinical Infectious Diseases</i> , 2016, 62, 919-926.	2.9	65
20	CD127 Expression, Exhaustion Status and Antigen Specific Proliferation Predict Sustained Virologic Response to IFN in HCV/HIV Co-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e101441.	1.1	13
21	Correlates of drug use cessation among participants in the Canadian HIV/HCV Co-infection Cohort. <i>Drug and Alcohol Dependence</i> , 2014, 137, 121-128.	1.6	13
22	Factors Associated With Discordance Between Absolute CD4 Cell Count and CD4 Cell Percentage in Patients Coinfected With HIV and Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2012, 54, 1798-1805.	2.9	18
23	Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2012, 26, 1789-1794.	1.0	16
24	Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV/hepatitis C virus co-infection. <i>Aids</i> , 2011, 25, 967-975.	1.0	31
25	Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. <i>Aids</i> , 2010, 24, 2639-2644.	1.0	5
26	HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. <i>European Journal of Immunology</i> , 2010, 40, 2493-2505.	1.6	87
27	Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study. <i>International Journal of Epidemiology</i> , 2010, 39, 1162-1169.	0.9	91
28	Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV/HCV coinfection before and after antiretroviral therapy. <i>Aids</i> , 2010, 24, 1857-1865.	1.0	71